Contact Us
Drug Search Results
More Filters [+]

Abaloparatide

Alternative Names: abaloparatide, ba058, tymlos
Latest Update: 2024-12-09
Latest Update Note: News Article

Product Description

Abaloparatide is used to treat osteoporosis in postmenopausal women who are at high risk for bone fracture. It reduces the risk of having bone and spine fracture in postmenopausal women with osteoporosis. (Sourced from: https://www.mayoclinic.org/drugs-supplements/abaloparatide-subcutaneous-route/side-effects/drg-20406221?p=1)

Mechanisms of Action: PTH Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous,Transdermal

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Croatia | Czech | European Medicines Agency | Finland | Iceland | Ireland | Italy | Japan | Lithuania | Poland | Portugal | Slovakia | Sweden | United States

Approved Indications: Osteoporosis | Osteoporosis, Postmenopausal

Known Adverse Events: Hypotension | Hypotension, Orthostatic | Abdominal Pain | Dizziness | Headache | Pain Unspecified | Vertigo | Hyperparathyroidism | Hyperparathyroidism, Primary | Drug Hypersensitivity | Hypercalcemia | Pregnancy Outcomes | Pregnancy, Abdominal | Urolithiasis | Hypercalciuria

Company: Radius Health
Company Location: BOSTON MA 02210
Company CEO: G. Kelly Martin
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Abaloparatide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Osteoporosis|Osteoporosis, Postmenopausal|Femoral Fractures

Phase 3: Osteoporosis, Postmenopausal|Osteoporosis|Osteoporotic Fractures

Phase 2: Osteoporosis, Postmenopausal|Low Back Pain|Intervertebral Disc Degeneration|Hip Fracture|Osteoporosis|Kyphosis

Phase 1: Osteoporosis|Osteoporosis, Postmenopausal|Bone Diseases, Metabolic|Preleukemia|Myelodysplastic Syndrome|Juvenile Myelomonocytic Leukemia,|Chronic Myelomonocytic Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT04467983

P4

Recruiting

Osteoporosis, Postmenopausal

2026-04-01

NCT04626141

P4

Withdrawn

Femoral Fractures

2025-06-01

A534255

P4

Active, not recruiting

Osteoporosis

2025-03-01

NCT03841058

P2

Recruiting

Low Back Pain|Kyphosis

2024-10-01

Recent News Events

Date

Type

Title

01/02/2025

News Article

 Radius Pharmaceuticals Announces Licensing Agreement with Pharmanovia to Register and Commercialize Abaloparatide in China and Select Asia Pacific Territories

12/09/2024

News Article

 Radius Pharmaceuticals Expands Abaloparatide Licensing Agreement with Theramex Granting Additional Commercialization Rights Including Mexico, Canada, South Africa, Israel, and Russia

11/27/2024

News Article

 Pharmaceutical Executive® announces winners of 2024 Pharmaceutical Executive APEX Awards

04/16/2024

News Article

 Radius Announces Presentation of Data on TYMLOS (abaloparatide) at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions